Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 Diabetes
Authors' conclusion
Advanced hybrid closed-loop systems improve glucose control with a reasonable safety profile and high treatment satisfaction. Skin problems are common adverse events.
Study context
- Population
- Adults with T1D treated at any time with Tandem Control IQ (TCIQ) or MiniMed 780G, six diabetes outpatient clinics in Sweden; mean age 42 years, 40.8% female, 65% used TCIQrandomly selected
- Participants
- 142 adults
- Exposure
- Advanced hybrid closed-loop (AHCL) systems: after vs before
- Outcome
- HbA1c
- Follow-up
- Median 1.7 years
Methodological detailsmulticentre, randomly selected participants, questionnaires
- Multicentre
- Randomly selected participants
- Questionnaires
Main finding
As reported in the abstract
- Hemoglobin A1c (HbA1c) reduced by 0.6% (6.8 mmol/mol), 95% CI 0.5-0.8% (5.3-8.2 mmol/mol), P < .001
- HbA1c from 7.3% to 6.7% (57-50 mmol/mol)
Observational data: associations, not effects.
Further findings
Time in range (TIR)
- TIR increased by 14.5%
- 57.0% to 71.5% (95% CI 12.2%-16.9%; P < .001)
Time below range (TBR) (<70 mg/dL, <3.9 mmol/L)
- TBR decreased (P < .001)
- 3.8% to 1.6%
SD of glucose
- SD reduced, 61 to 51 mg/dL (3.4-2.9 mmol/L), P < .001
CV of glucose
- CV reduced (P < .001)
- 35% to 33%
Treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire (DTSQ) change version, range −18 to 18)
- Treatment satisfaction increased, DTSQ score (P < .001)
- 14.8
Safety
Severe hypoglycaemia
- Severe hypoglycemia events
- 4
Ketoacidosis
- Cases of ketoacidosis
- 0
Skin problems
- Skin problems in study population
- 32.4%
Original publication
Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 Diabetes. J Diabetes Sci Technol. Published 17 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →